Full Paper
solvent was removed under reduced pressure. Specific details for
each compound are given below.
24.8, 25.9, 46.1, 112.8, 113.9, 119.8, 137.3, 137.4, 154.2, 156.9, 159.5,
194.6 ppm. IR (KBr): ν = 2935, 2854, 1706, 1616, 1539, 1461,
˜
1421 cm–1. C14H15N3O (241.29): calcd. C 69.69, H 6.27, N 17.41;
found C 69.43, H 6.61, N 17.06.
3,7-Dimethyl-2,4-di(piperidin-1-yl)-1,8-naphthyridine (15): Pre-
pared from 14 (1.20 g, 4.4 mmol) and piperidine (2.5 mL,
25.6 mmol). Purification by column chromatography (ethyl acetate, 7-(Morpholin-4-yl)-1,8-naphthyridine-2-carbaldehyde (4): Pre-
1
Rf = 0.42) gave 15 (0.60 g, 1.8 mmol, 42 %); m.p. 69–72 °C. H NMR pared from 7-methyl-2-(morpholin-1-yl)-1,8-naphthyridine (12;
(500 MHz, CDCl3): δ = 1.64–1.66 (m, 2 H), 1.70–1.75 (m, 10 H), 2.29
(s, 3 H), 2.69 (s, 3 H), 3.24–3.26 (m, 4 H), 3.28–3.32 (m, 4 H), 7.06 (d,
J = 8.3 Hz, 1 H), 8.17 (d, J = 8.3 Hz, 1 H) ppm. 13C NMR (125 MHz,
CDCl3): δ = 16.9, 24.6, 24.8, 25.1, 26.0, 27.0, 50.7, 52.4, 115.3, 117.4,
0.50 g, 2.2 mmol) and SeO2 (0.24 g, 2.2 mmol). Recrystallization
from ethyl acetate gave 4 (0.29 g, 1.2 mmol, 55 %); m.p. 192–193 °C.
1H NMR (500 MHz, CDCl3): δ = 3.85–3.91 (m, 8 H), 7.14 (d, J = 9.1 Hz,
1 H), 7.83 (d, J = 7.9 Hz, 1 H), 7.97 (d, J = 9.1 Hz, 1 H), 8.10 (dd, J =
7.9, 0.8 Hz, 1 H), 10.25 (d, J = 0.7 Hz, 1 H) ppm. 13C NMR (125 MHz,
118.6, 133.2, 155.4, 156.5, 160.3, 166.1 ppm. IR (KBr): ν = 2931, 2848,
˜
1581, 1540, 1463, 1450 cm–1. C20H28N4 (324.47): calcd. C 74.03, H CDCl3): δ = 45.2, 66.7, 112.3, 114.6, 120.1, 137.6, 137.9, 154.4, 156.4,
8.70, N 17.27; found C 73.99, H 8.68, N 17.17.
159.7, 194.3 ppm. IR (KBr): ν = 2966, 2815, 1700, 1612, 1512, 1440,
˜
1419 cm–1. C13H13N3O2 (243.26): calcd. C 64.19, H 5.39, N 17.27;
found C 64.24, H 5.57, N 17.16.
3,7-Dimethyl-4-(morpholin-4-yl)-2-(piperidin-1-yl)-1,8-naphthyr-
idine (16): Prepared from 14 (1.00 g, 3.6 mmol) and morpholine
(2.5 mL, 38.3 mmol). Purification by column chromatography (ethyl
acetate, Rf = 0.30) gave 16 (0.30 g, 0.9 mmol, 25 %); m.p. 144–
145 °C. 1H NMR (500 MHz, CDCl3): δ = 1.64–1.67 (m, 2 H), 1.70–1.75
(m, 4 H), 2.34 (s, 3 H), 2.70 (s, 3 H), 3.30–3.33 (m, 8 H), 3.90–3.92 (m,
4 H), 7.09 (d, J = 8.2 Hz), 8.20 (d, J = 8.2 Hz, 1 H) ppm. 13C NMR
(125 MHz, CDCl3): δ = 16.7, 24.7, 25.1, 26.0, 50.7, 51.0, 67.9, 114.9,
5,7-Dichloro-6-Methyl-1,8-naphthyridine-2-carbaldehyde (5):
Prepared from 2,4-dichloro-3,7-dimethyl-1,8-naphthyridine (13;
1.00 g, 4.4 mmol) and SeO2 (0.50 g, 4.4 mmol). Yield: 0.31 g
1
(1.3 mmol, 30 %); m.p. 138–143 °C. H NMR (500 MHz, CDCl3): δ =
2.69 (s, 3 H), 8.12 (d, J = 8.5 Hz, 1 H), 8.66 (dd, J = 8.5, 0.8 Hz, 1 H),
10.20 (d, J = 0.7 Hz, 1 H) ppm. 13C NMR (125 MHz, CDCl3): δ = 18.1,
119.1, 123.2, 132.3, 135.8, 142.7, 153.1, 155.0, 156.6, 192.6 ppm. IR
118.4, 119.0, 132.7, 154.6, 155.5, 160.7, 166.0 ppm. IR (KBr): ν = 2850,
˜
2813, 1600, 1581, 1454, 1448 cm–1. C19H26N4O (326.44): calcd. C
69.91, H 8.03, N 17.16; found C 70.19, H 8.22, N 17.25.
(KBr): ν = 3064, 1707, 1577, 1539, 1133 cm–1. C10H6Cl2N2O (241.08):
˜
calcd. C 49.82, H 2.51, N 11.62; found C 49.90, H 2.60, N 11.44.
General Procedure for the Preparation of Compounds 1–8: A
mixture of the corresponding 1,8-naphthyridine (compounds 9–16),
an equimolar amount of SeO2, three drops of water and 1,4-dioxane
(30 mL) were stirred for 4 h at 50 °C. After filtration of SeO2 through
5-Chloro-6-methyl-7-(piperidin-1-yl)-1,8-naphthyridine-2-carb-
aldehyde (6): Prepared from 4-chloro-3,7-dimethyl-2-(piperidin-1-
yl)-1,8-naphthyridine (14) (0.80 g, 2.9 mmol) and SeO2 (0.31 g,
2.9 mmol). Yield: 0.55 g (1.0 mmol, 65 %); m.p. 131–136 °C. 1H NMR
Celite, the solvent was removed under reduced pressure. The pre- (500 MHz, CDCl3): δ = 1.71–1.73 (m, 2 H), 1.77–1.81 (m, 4 H), 2.53
cipitate was extracted with ethyl acetate, washed with a solution of (s, 3 H), 3.41–3.43 (m, 4 H), 7.95 (d, J = 8.2 Hz, 1 H), 8.54 (dd, J =
NaHCO3 and dried with Na2SO4. After removing the solvent, the
crude product was purified as given below.
8.2, 0.7 Hz, 1 H), 10.29 (d, J = 0.7 Hz, 1 H) ppm. 13C NMR (125 MHz,
CDCl3): δ = 17.8, 24.4, 25.8, 51.0, 116.0, 120.8, 127.0, 134.7, 142.0,
154.1, 165.2, 193.8 ppm. IR (KBr): ν = 2925, 2838, 1706, 1598, 1538,
˜
7-Chloro-1,8-naphthyridine-2-carbaldehyde (1): Prepared from
2-chloro-7-methyl-1,8-naphthyridine (9; 0.50 g, 2.8 mmol) and SeO2
(0.31 g, 2.8 mmol). Recrystallisation of the crude product from wa-
ter/ethanol gave 1 (0.30 g, 1.6 mmol, 56 %); m.p. 214–215 °C. 1H
NMR (500 MHz, CDCl3): δ = 7.64 (d, J = 8.3 Hz, 1 H), 8.16 (d, J =
8.4 Hz, 1 H), 8.25 (d, J = 8.4 Hz, 1 H), 8.41 (d, J = 8.2 Hz, 1 H), 10.29
1434, 1130 cm–1. C15H16ClN3O (289.76): calcd. C 62.18, H 5.57, N
14.50; found C 61.93, H 5.76, N 14.55.
3-Methyl-2,4-di(piperidin-1-yl)-1,8-naphthyridine-7-carbalde-
hyde (7): Prepared from 3,7-dimethyl-2,4-di(piperidin-1-yl)-1,8-
naphthyridine (15) (0.65 g, 2.0 mmol) and SeO2 (0.22 g, 2.0 mmol).
1
(s, 1 H) ppm. 13C NMR (125 MHz, CDCl3): δ = 118.7, 123.9, 125.9, Yield: 0.61 g (1.8 mmol, 90 %); m.p. 93–103 °C. H NMR (500 MHz,
138.6, 139.2, 155.1, 155.3, 155.7, 193.1 ppm. IR (KBr): ν = 3041, 1712,
CDCl3): δ = 1.58–1.71 (m, 12 H), 2.25 (s, 3 H), 3.18–3.32 (m, 8 H),
7.74 (d, J = 8.2 Hz, 1 H), 8.33 (dd, J = 8.2, 0.8 Hz, 1 H), 10.27 (d, J =
0.8 Hz) ppm. 13C NMR (125 MHz, CDCl3): δ = 17.6, 24.5, 24.7, 25.9,
26.9, 50.4, 52.4, 114.3, 120.2, 120.5, 134.3, 153.1, 155.5, 156.2, 166.8,
˜
1594, 1538, 1106 cm–1. C9H5ClN2O (192.60): calcd. C 56.12, H 2.62,
N 14.54; found C 55.93, H 2.88, N 14.78.
7-(Pyrrolidin-1-yl)-1,8-naphthyridine-2-carbaldehyde (2): Pre-
pared from 7-methyl-2-(pyrrolidin-1-yl)-1,8-naphthyridine (10; 0.3 g,
1.4 mmol) and SeO2 (0.15 g, 1.4 mmol). Yield: 0.20 g (0.9 mmol,
194.7 ppm. IR (KBr): ν = 2931, 2846, 1704, 1579, 1540, 1463,
˜
1438 cm–1. C20H26N4O (338.45): calcd. C 70.98, H 7.74, N 16.55;
found C 70.84, H 7.83, N 16.84.
1
63 %); m.p. 151 °C. H NMR (500 MHz, CDCl3): δ = 2.08–2.10 (m, 4
H), 3.50–3.90 (m, 4 H), 6.89 (d, J = 9.0 Hz, 1 H), 7.74 (d, J = 7.9 Hz,
1 H), 7.86 (d, J = 9.0 Hz, 1 H), 8.03 (dd, J = 7.9, 0.8 Hz, 1 H), 10.26
3-Methyl-4-(morpholin-4-yl)-2-(piperidin-1-yl)-1,8-naphthyr-
idine-7-carbaldehyde (8): Prepared from 3,7-dimethyl-4-(morphol-
(d, J = 0.8 Hz, 1 H) ppm. 13C NMR (125 MHz, CDCl3): δ = 25.5, 47.2, in-4-yl)-2-(piperidin-1-yl)-1,8-naphthyridine (16, 0.19 g, 0.6 mmol)
113.5, 113.9, 119.7, 136.9, 137.5, 154.0, 157.0, 158.0, 194.7 ppm. IR and SeO2 (0.06 g, 0.6 mmol). Yield: 0.11 g 0.3 mmol, 55 %); m.p.
(KBr): ν = 2952, 2865, 1693, 1613, 1535, 1473, 1456 cm–1. C13H13N3O 178–179 °C. 1H NMR (500 MHz, CDCl3): δ = 1.68–1.71 (m, 2 H), 1.74–
˜
(227.27): calcd. C 68.70, H 5.77, N 18.49; found C 68.54, H 5.94, N
18.21.
1.78 (m, 4 H), 2.39 (s, 3 H), 3.35–3.42 (m, 6 H), 3.93–3.95 (m, 4 H),
7.85 (d, J = 8.3 Hz, 1 H), 8.46 (dd, J = 8.3, 0.7 Hz, 1 H), 10.27 (d, J =
0.7 Hz, 1 H, CHO) ppm. 13C NMR (125 MHz, CDCl3): δ = 17.5, 24.6,
25.9, 50.5, 51.0, 67.8, 114.6, 120.1, 121.2, 134.0, 153.4, 154.4, 155.5,
166.7, 194.5 ppm. C19H24N4O2 (340.42): calcd. C 67.04, H 7.11, N
16.46; found C 66.81, H 7.49, N 16.26.
7-(Piperidin-1-yl)-1,8-naphthyridine-2-carbaldehyde (3): Pre-
pared from 7-methyl-2-(piperidin-1-yl)-1,8-naphthyridine (11;
0.80 g, 3.5 mmol) and SeO2 (0.39 g, 3.5 mmol). Purification by col-
umn chromatography (ethyl acetate, Rf = 0.68) gave 3 (0.60 g,
2.4 mmol, 71 %); m.p. 102–105 °C. 1H NMR (500 MHz, CDCl3): δ =
X-ray Crystal Structure Determination: Crystals of the com-
1.68–1.75 (m, 6 H), 3.87–3.89 (m, 4 H), 7.15 (d, J = 9.1 Hz, 1 H), 7.76 pounds studied were grown by slow evaporation of the solvent
(d, J = 7.9 Hz, 1 H), 7.88 (d, J = 9.1 Hz, 1 H), 8.03 (dd, J = 7.9, 0.8 Hz,
(solvent mixtures) at room temperature. Crystals suitable for X-ray
diffraction experiments were selected under a microscope and
1 H), 10.25 (d, J = 0.8 Hz, 1 H) ppm. 13C NMR (125 MHz, CDCl3): δ =
Eur. J. Org. Chem. 2017, 6038–6051
6049
© 2017 Wiley-VCH Verlag GmbH & Co. KGaA, Weinheim